These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34724396)

  • 1. In type 2 diabetes, tirzepatide reduced HbA
    Gandhi GY
    Ann Intern Med; 2021 Nov; 174(11):JC127. PubMed ID: 34724396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Add-on value of tirzepatide versus semaglutide.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):377-378. PubMed ID: 35468323
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
    Vadher K; Patel H; Mody R; Levine JA; Hoog M; Cheng AY; Pantalone KM; Sapin H
    Diabetes Obes Metab; 2022 Sep; 24(9):1861-1868. PubMed ID: 35589616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
    Frias JP; De Block C; Brown K; Wang H; Thomas MK; Zeytinoglu M; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1745-1753. PubMed ID: 38252888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
    Osumili B; Fan L; Paik JS; Pantalone KM; Ranta K; Sapin H; Tofé S
    Diabetes Res Clin Pract; 2024 Jun; 212():111717. PubMed ID: 38777128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In type 2 diabetes with increased CV risk, tirzepatide reduced HbA
    Singh M
    Ann Intern Med; 2022 Mar; 175(3):JC34. PubMed ID: 35226523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirzepatide (Mounjaro) for type 2 diabetes.
    Med Lett Drugs Ther; 2022 Jul; 64(1654):105-107. PubMed ID: 35802842
    [No Abstract]   [Full Text] [Related]  

  • 11. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
    Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
    Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
    Frias JP; Nauck MA; Van J; Benson C; Bray R; Cui X; Milicevic Z; Urva S; Haupt A; Robins DA
    Diabetes Obes Metab; 2020 Jun; 22(6):938-946. PubMed ID: 31984598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 17. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
    Zaheer H; Hammad Zaheer M
    Diabetes Res Clin Pract; 2024 Jul; 213():111759. PubMed ID: 38925293
    [No Abstract]   [Full Text] [Related]  

  • 18. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
    Reitzel SB; Bøgelund M; Basse A; Barszczewska O; Ren H
    Curr Med Res Opin; 2023 Aug; 39(8):1055-1060. PubMed ID: 37415503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
    Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL
    J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.